TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06033209

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N332-GT5 gp140 (IM, Bolus)
Description: IM in the deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N332-GT5 gp140 (IM, Bolus)
Description: IM in the deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N332-GT5 gp140 (IM, Bolus)
Description: IM in the deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N332-GT5 gp140 (IM, Bolus)
Description: IM in the deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N332-GT5 gp140 (IM, Fractioned)
Description: IM in the deltoid, Fractionated escalating dose for prime

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N332-GT5 gp140 (IM, Fractioned)
Description: IM in the deltoid, Fractionated escalating dose for prime

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N332-GT5 gp140 (SC, Bolus)
Description: SC in the upper arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N332-GT5 gp140 (SC, Bolus)
Description: SC in the upper arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N332-GT5 gp140 (SC, Bolus)
Description: SC in the upper arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N332-GT5 gp140 (SC, Bolus)
Description: SC in the upper arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N332-GT5 gp140 (SC, Bolus)
Description: SC in the upper arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N332-GT5 gp140 (SC, Bolus)
Description: SC in the upper arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N332-GT5 gp140 (SC, Fractioned)
Description: SC in the upper arm, Fractionated escalating dose for prime

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N332-GT5 gp140 (SC, Fractioned)
Description: SC in the upper arm, Fractionated escalating dose for prime

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SMNP (IM, Bolus)
Description: IM in the deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SMNP (IM, Bolus)
Description: IM in the deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SMNP (IM, Bolus)
Description: IM in the deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SMNP (IM, Bolus)
Description: IM in the deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SMNP (IM, Bolus)
Description: IM in the deltoid
Study: NCT06168409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baxdrostat
Description: Baxdrostat tablet administered orally, once daily (QD). Unit dose strength:~• 2 mg per tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet matching baxdrostat, administered orally, once daily (QD).
Study: NCT06033209

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SMNP (IM, Bolus)
Description: IM in the deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SMNP (IM, Fractioned)
Description: IM in the deltoid, Fractionated escalating dose for prime
Study: NCT04737174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ES-481
Description: 28-day screening period followed by 4-week dose escalation period followed by 16-week treatment period followed by 4-week dose washout period
Study: NCT05377099

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CORVIS
Description: Measurement of the DA ratio, IR and SSI before and after for patients under gone LASIK, femto LASIK and PRK using the CORVIS device.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CORVIS
Description: Measurement of the DA ratio, IR and SSI before and after for patients under gone LASIK, femto LASIK and PRK using the CORVIS device.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CORVIS
Description: Measurement of the DA ratio, IR and SSI before and after for patients under gone LASIK, femto LASIK and PRK using the CORVIS device.
Study: NCT06033209

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SMNP (IM, Fractioned)
Description: IM in the deltoid, Fractionated escalating dose for prime
Study: NCT05101330

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilingual prescription medication labels
Description: The bilingual PML contains English and Chinese medication-related instructions for participants.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilingual prescription medication labels
Description: The bilingual PML contains English and Chinese medication-related instructions for participants.
Study: NCT04647136

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Fertility Health Screening
Description: Basic fertility health screening comprising an anti-Mullerian hormone (AMH) test and semen analysis, a doctor's consultation to explain the results, and standardised reproductive counselling by a trained nurse comprising a discussion of reproductive plans (including addressing barriers the couple face), education on age-related fertility decline and limitations of artificial reproductive technologies, advice on the optimal reproductive timing and when to seek further help. An educational brochure will be handed to the couple during the counselling session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fertility Awareness Tools
Description: Online intervention consisting of 1) video targeting fertility education and specific attitudes, social norms and perceived control for having children, 2) a fertility awareness tool (FERTISTAT) and 3) an educational brochure on fertility. This intervention can be self-administered and is therefore easily scalable.
Study: NCT05712811

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CRYOTHERAPY
Description: Group A had their warts treated once every two weeks for a total of twelve weeks, with liquid nitrogen using cryoget method for 10 to 15 seconds on each lesion (depending on size, until a narrow white rim of around 1 mm developed around it).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tricholoracetic acid
Description: Group B were treated with liquid TCA 90% by an applicator every two weeks for a total of twelve weeks. After 20 minutes, patients were instructed to remove the solution by washing their warts with water or regular saline.
Study: NCT06033209

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SMNP (SC, Bolus)
Description: SC in the upper arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SMNP (SC, Bolus)
Description: SC in the upper arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SMNP (SC, Bolus)
Description: SC in the upper arm
Study: NCT04924582

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Capacity Coaching
Description: Capacity Coaching focuses on developing the capacity within patients to adapt, endure, and function optimally in their lives along with illness and treatment.
Study: NCT05323110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBS001
Description: Intravenously administered, humanised anti-LIGHT IgG monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBS001
Description: Intravenously administered, humanised anti-LIGHT IgG monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBS001
Description: Intravenously administered, humanised anti-LIGHT IgG monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBS001
Description: Intravenously administered, humanised anti-LIGHT IgG monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBS001
Description: Intravenously administered, humanised anti-LIGHT IgG monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBS001
Description: Intravenously administered, humanised anti-LIGHT IgG monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBS001
Description: Intravenously administered, humanised anti-LIGHT IgG monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBS001
Description: Intravenously administered, humanised anti-LIGHT IgG monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBS001
Description: Intravenously administered, humanised anti-LIGHT IgG monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBS001
Description: Intravenously administered, humanised anti-LIGHT IgG monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBS001
Description: Intravenously administered, humanised anti-LIGHT IgG monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: CBS001 matched placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: CBS001 matched placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: CBS001 matched placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: CBS001 matched placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: CBS001 matched placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: CBS001 matched placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: CBS001 matched placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: CBS001 matched placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: CBS001 matched placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: CBS001 matched placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: CBS001 matched placebo
Study: NCT05489133

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified prolonged exposure
Description: Imaginary and in vivo expo, in addition to psychoeducation
Study: NCT05020678

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKX019
Description: NKX019 is an investigational allogeneic CAR NK product targeting CD19 on cells. The starting dose of NKX019 in Part 1 is 3 × 10\^8 NK cells (6 × 10\^6/kg for patients \< 50 kg) administered as 3 weekly doses. Part 2 (dose expansion cohorts) will use the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of NKX019 as determined in Part 1.
Study: NCT04775212

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desﬂurane
Description: compare effects of inhaled anaesthetic desflurane and sevoflurane on liver functions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane
Study: NCT05293132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast Sodium 10 mg
Description: Film coated tablets containing 10 mg montelukast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-Enzyme Q10
Description: Capsules contain 210 mg Co-Enzyme Q10
Study: NCT04996823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Participants will receive ipilimumab 3mg/kg IV every 3 weeks for up to 4 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Participants will take 5 mg Axitinib twice daily by mouth for up to 35 cycles (24 months)
Study: NCT05293132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Treatment
Description: Standard sepsis treatment includes fluid resuscitation, early administration of intravenous broad spectrum antibiotic (ceftriaxone 2gm/24 hour or meropenem 1g/8 hours, linezolid 600/12hours) till obtaining the microbiological culture to narrow the coverage, paracetamol intravenous antipyretic (paracetamol 1gm/8 hours) till no fever and temperature less than 380c, and prophylactic anticoagulant low molecular weight heparin (enoxaparin 40/24 hours), prophylactic stress ulcer (pantoprazole 40mg/24hours)
Study: NCT05104554

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron and folic acid (IFA)
Description: IFA: Weekly regimen of one tablet containing iron (60 mg) and folic acid (2800 μg)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multiple Micronutrient Supplement (MMS)
Description: MMS: Daily regimen of one multiple micronutrient tablet containing fifteen micronutrients in the United Nations International Multiple Micronutrient Preparation (UNIMMAP) preparation. Composition includes vitamin A (800 ug), vitamin D (5 ug), vitamin E (10 mg), vitamin C (70 mg), vitamin B1 (1.4 mg), vitamin B2 (1.4 mg), niacin (18 mg), vitamin B6 (1.9 mg), vitamin B12 (2.6 ug), folic acid (400 ug), iron (30 mg), zinc (15 mg), copper (2 mg), selenium (65 ug), and iodine (150 ug).
Study: NCT05293132

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Standard sepsis treatment includes fluid resuscitation, early administration of intravenous broad spectrum antibiotic (ceftriaxone 2gm/24 hour or meropenem 1g/8 hours, linezolid 600/12hours) till obtaining the microbiological culture to narrow the coverage, paracetamol intravenous antipyretic (paracetamol 1gm/8 hours) till no fever and temperature less than 380c, and prophylactic anticoagulant low molecular weight heparin (enoxaparin 40/24 hours), prophylactic stress ulcer (pantoprazole 40mg/24hours)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Treatment
Description: Standard sepsis treatment includes fluid resuscitation, early administration of intravenous broad spectrum antibiotic (ceftriaxone 2gm/24 hour or meropenem 1g/8 hours, linezolid 600/12hours) till obtaining the microbiological culture to narrow the coverage, paracetamol intravenous antipyretic (paracetamol 1gm/8 hours) till no fever and temperature less than 380c, and prophylactic anticoagulant low molecular weight heparin (enoxaparin 40/24 hours), prophylactic stress ulcer (pantoprazole 40mg/24hours)
Study: NCT05998824

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: SCD-specific COVID-19 vaccination information (SCVI) video
Description: SCD-specific COVID-19 vaccination information (SCVI) video developed by health care providers with input from a community advisory board of people with sickle cel disease and their caregivers.
Study: NCT06269367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NewGait
Description: wearable limb orthotic device

Intervention type: OTHER
Group type: OTHER
Intervention: Control wearable limb orthotic device
Description: wearable limb orthotic device
Study: NCT05895825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EOC237
Description: EOC237 for orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EOC237
Description: EOC237 for orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EOC237
Description: EOC237 for orally
Study: NCT06453447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 40 mg PO once daily for 14 days starting day of surgery
Study: NCT05658536

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 6-Week Self-Management Group
Description: The goal of the 6-session group-based intervention for patients with Post-COVID is to teach patients behavioral strategies known to be helpful in managing several common Post-COVID symptoms, including fatigue, memory and attention issues, poor sleep, breathlessness, coping with anxiety and uncertainty, and stress management. It is currently available to patients who are seen in the Post-COVID-19 Rehabilitation and Recovery Clinic at UW and the Post-COVID-19 Clinic in VAPSHCS Rehabilitation Care Services.
Study: NCT05361057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax, Azacitidine
Description: The patients were administrated with azacytidine 75 mg/m2 d1-7，venetoclax: 100mg d1, 200mg d2, 400mg d3-21;

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venetoclax, daunorubicin, cytarabine
Description: The patients were administrated with daunorubicin：45mg/m2 d1-2, cytarabine:100mg/ m2 d1-5, venetoclax: 100mg d1, 200mg d2, 400mg d3-14
Study: NCT05407610

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Radiofrequency ablation of the genicular nerves
Description: Conventional Radiofrequency treatment of the genicular nerves of the knee blocks the transmission of painful stimuli from the sensory genicular nerves of the knee to the central nervous system by means of a thermal lesion created using RF current.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cooled Radiofrequency ablation of the genicular nerves
Description: Cooled RF treatment causes a larger lesion size compared to conventional RF by means of internal cooling of the probe.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: Sham procedure with placing of needles subcutaneously.
Study: NCT06136247

Intervention type: DIAGNOSTIC_TEST
Intervention: Neurocognitive battery
Description: The Penn Computerized Neurobehavioral Battery (CNB) consists of a series of cognitive tasks, measuring accuracy and speed of performance in major cognitive domains, including executive functions (i.e., abstraction, sustained attention, working memory), episodic memory (i.e., verbal, facial, and spatial memory), complex cognitive processing (i.e., language reasoning, nonverbal reasoning, spatial processing), social cognition (i.e., emotion identification, emotion intensity differentiation, age differentiation) and processing speed (i.e., sensorimotor and motor).

Intervention type: DIAGNOSTIC_TEST
Intervention: Neurocognitive battery
Description: The Penn Computerized Neurobehavioral Battery (CNB) consists of a series of cognitive tasks, measuring accuracy and speed of performance in major cognitive domains, including executive functions (i.e., abstraction, sustained attention, working memory), episodic memory (i.e., verbal, facial, and spatial memory), complex cognitive processing (i.e., language reasoning, nonverbal reasoning, spatial processing), social cognition (i.e., emotion identification, emotion intensity differentiation, age differentiation) and processing speed (i.e., sensorimotor and motor).

Intervention type: DIAGNOSTIC_TEST
Intervention: fNIRS
Description: Functional near-infrared spectroscopy (fNIRS) is a noninvasive optical imaging technique that measures changes in oxygenated and deoxygenated hemoglobin (Hb) concentrations within the brain by means of their characteristic absorption spectra of the wavelengths range of 700-1000 nm \[35,36\].

Intervention type: DIAGNOSTIC_TEST
Intervention: fNIRS
Description: Functional near-infrared spectroscopy (fNIRS) is a noninvasive optical imaging technique that measures changes in oxygenated and deoxygenated hemoglobin (Hb) concentrations within the brain by means of their characteristic absorption spectra of the wavelengths range of 700-1000 nm \[35,36\].
Study: NCT06096337

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FARAPULSE™ Pulsed Field Ablation (PFA) System
Description: Subjects will undergo a pulsed field ablation procedure using the FARAPULSE™ Pulsed Field Ablation (PFA) System for the isolation of pulmonary veins and posterior wall.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone
Description: Anti-Arrhythmic Drugs (AADs) including, Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone will be prescribed and monitored in accordance with local clinical practice and already established guideline-directed therapy for patients with persistent atrial fibrillation (AF).
Study: NCT06278389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACC017 tablets
Description: ACC017 tablets 5 mg, 20 mg, 40 mg, 80 mg, 120 mg, and 160 mg (tentative) with matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACC017 tablets
Description: ACC017 tablets 5 mg, 20 mg, 40 mg, 80 mg, 120 mg, and 160 mg (tentative) with matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine and Tenofovir Alafenamide Fumarate Tablets
Description: Participants received a single oral dose of ACC017 tablets with emtricitabine and tenofovir alafenamide fumarate tablets under the fasting condition.
Study: NCT01351038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicine, Oxaliplatin, Capecitabine, Panitumumab
Description: 3 cycles (repeated q 21d) Epirubicine 50mg/m² i.v. d1 Oxaliplatin 100mg/m² i.v. d1 Panitumumab 9mg/kg i.v. d1 Capecitabine 500mg/m² bid d1-21
Study: NCT06033209

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SMNP (SC, Bolus)
Description: SC in the upper arm
Study: NCT05790239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3,4-methylenedioxymethamphetamine
Description: Initial doses per Experimental Session include 68 mg or 100 mg MDMA (equivalent to 80 mg or 120 mg MDMA HCl), followed 1.5 to 2 hours later by a supplemental dose of 34 mg or 50 mg MDMA (equivalent to 40 mg or 60 mg MDMA HCl).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: d-amphetamine
Description: Initial dose per experimental session will be 5 mg or 10 mg d-amphetamine, followed 1.5 to 2 hours later by supplemental dose of 2.5 mg or 5 mg d-amphetamine.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapy
Description: Participants assigned to MDMA and d-amphetamine will undergo a therapeutic approach, which is detailed in the MDMA-Assisted Therapy Treatment Manual and administered by MAPS-trained therapists. In brief, this therapy is guided by the subject's own recollections of traumatic events. The subject and two therapists provide a comfortable and supportive environment and allow the subject to guide the discussion. Subjects are encouraged to experience and express fear, anger, and grief with less likelihood of feeling overwhelmed by these emotions. MDMA seems to engender internal awareness that even painful feelings that arise are an important part of the therapeutic process. In addition, feelings of empathy, love, and deep appreciation often emerge, along with a clearer perspective of the trauma as a past event, a more accurate perspective about its significance, and a heightened awareness of the support and safety that exists in the present.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy
Description: Participants assigned to MDMA and d-amphetamine will undergo a therapeutic approach, which is detailed in the MDMA-Assisted Therapy Treatment Manual and administered by MAPS-trained therapists. In brief, this therapy is guided by the subject's own recollections of traumatic events. The subject and two therapists provide a comfortable and supportive environment and allow the subject to guide the discussion. Subjects are encouraged to experience and express fear, anger, and grief with less likelihood of feeling overwhelmed by these emotions. MDMA seems to engender internal awareness that even painful feelings that arise are an important part of the therapeutic process. In addition, feelings of empathy, love, and deep appreciation often emerge, along with a clearer perspective of the trauma as a past event, a more accurate perspective about its significance, and a heightened awareness of the support and safety that exists in the present.